Skip to main content
KPC PHARMACEUTICALS, INC. logo

KPC PHARMACEUTICALS, INC. — Investor Relations & Filings

Ticker · 600422 ISIN · CNE0000015P8 LEI · 3003007ZALHXKUFMKN96 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 2,727 across all filing types
Latest filing 2018-09-27 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 600422

About KPC PHARMACEUTICALS, INC.

https://en.kpc.com.cn/

KPC Pharmaceuticals, Inc. specializes in the research, development, and manufacturing of pharmaceutical products, with a significant focus on natural and botanical medicines. The company is a global leader in the production of artemisinin-based anti-malarial treatments, including artemether and its derivatives. Its portfolio encompasses a wide range of therapeutic areas, notably cardiovascular and cerebrovascular health, where it utilizes Panax notoginseng saponins as a core component. KPC integrates traditional medicinal knowledge with modern pharmacological techniques to develop standardized botanical extracts and chemical drugs. The organization operates extensive production facilities and research centers dedicated to drug discovery and quality control. Its business activities extend to the distribution of healthcare products and the provision of medical services, aiming to provide comprehensive health solutions through innovation in natural medicine and biotechnology.

Recent filings

Filing Released Lang Actions
关于全资子公司昆明中药厂有限公司获得药品GMP证书的公告
Regulatory Filings Classification · 95% confidence The document is an official announcement from Kunming Pharmaceutical Group Co., Ltd. regarding its wholly-owned subsidiary obtaining GMP (Good Manufacturing Practice) certificates issued by the Yunnan Food and Drug Administration. The content details the certificate numbers, certification scope, production lines, product types, market data, and the impact of the certification on the company. There is no financial data, quarterly or annual report content, nor is it a transcript, proxy, or legal proceeding. The document is a regulatory announcement about a certification achievement relevant to production quality compliance. It is not a financial report or management change announcement. Given the nature of the content and the absence of financial statements or voting results, the best fitting category is Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other specific categories. The document length is 4182 characters, which is not extremely short, but the content is clearly an announcement rather than a report publication notice or certification letter. Therefore, classification as RNS is appropriate with high confidence.
2018-09-27 Chinese
关于完成经营范围变更工商登记的公告
Regulatory Filings Classification · 95% confidence The document is an official announcement from Kunming Pharmaceutical Group Co., Ltd. regarding the completion of a change in the company's business scope registration with the industrial and commercial administration. It references board and shareholder meetings where the change was approved and states that the company has obtained a new business license reflecting the updated business scope. The document is short (633 characters) and serves as a formal notification of a corporate administrative update rather than a detailed report or financial statement. It does not contain financial data, audit information, or detailed management discussion. It is not a report publication announcement since it does not mention any report being published or attached. The content fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other categories.
2018-09-24 Chinese
关于东方金诚国际信用评估有限公司终止“15昆药债”评级的提示性公告
Regulatory Filings Classification · 95% confidence The document is a short announcement regarding the termination of the credit rating for a specific bond ('15 昆药债') by the rating agency 东方金诚国际信用评估有限公司. It states that the bond has been fully repaid and the rating is therefore terminated. The document is brief (597 characters) and serves as a notification rather than a detailed financial report or audit. It does not contain financial statements or detailed analysis, nor does it announce a meeting or voting results. It is an official regulatory announcement related to credit rating status, which fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2018-09-19 Chinese
回购实施结果暨股份变动公告
Transaction in Own Shares Classification · 100% confidence The document is a formal announcement from Kunming Pharmaceutical Group Co., Ltd. regarding the implementation results of a share repurchase program and subsequent changes in shareholding. It details the approval process, execution, and completion of the share buyback, including specific numbers of shares repurchased, prices, and the impact on share capital. It also reports on insider trading activity during the repurchase period and the cancellation of repurchased shares. The document is not a financial report, earnings release, or management discussion but a disclosure about the company's own share transactions. This fits the definition of a 'Transaction in Own Shares' filing, which reports on the company's buyback or sale of its own shares.
2018-09-12 Chinese
关于回购股份的实施进展情况公告
Transaction in Own Shares Classification · 100% confidence The document is an announcement from Kunming Pharmaceutical Group Co., Ltd. regarding the progress of its share repurchase program. It details the number of shares repurchased, the proportion of total shares, transaction prices, and total funds used. The document references previous announcements and regulatory compliance but does not contain financial statements or detailed financial analysis. The content focuses on the company's buyback activity, which fits the category of a report on transactions in own shares (share repurchase). The document length is short and it is not a report publication announcement or regulatory filing. Therefore, the appropriate classification is 'Transaction in Own Shares' (POS).
2018-09-04 Chinese
关于获得云南省科学技术进步奖的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement about receiving a scientific and technological progress award from the Yunnan provincial government. It contains no financial data, no mention of financial results, no regulatory filings, no meeting materials, no voting results, no management changes, no capital or financing updates, and no legal proceedings. The document is a public announcement of an award received, which does not fit into any specific financial report category. It is a general regulatory announcement about a non-financial event. Therefore, the best fitting category is Regulatory Filings (RNS). The document length is short and it is not a report publication announcement or certification.
2018-08-31 Chinese

Browse filings by year

26 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.